Skip to main content
Industry News
Emergent signs deal to make J&J COVID-19 vaccine

Emergent BioSolutions signed a five-year contract with Johnson & Johnson to manufacture the drug substance in a COVID-19 vaccine scheduled for human testing this month. Emergent's Baltimore Bayview facility is an HHS-designated Center for Innovation in Advanced Development and Manufacturing and reportedly can make hundreds of millions of vaccine doses yearly.

Full Story: